Search results for "Survival"

showing 10 items of 3291 documents

Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study

2016

Background Luminal A breast cancers respond well to anti-hormonal therapy (HT), are associated with a generally favorable prognosis and constitute the majority of breast cancer subtypes. HT is the mainstay of treatment of these patients, accompanied by an acceptable profile of side effects, whereas the added benefit of chemotherapy (CHT), including anthracycline and taxane-based programs, is less clear-cut and has undergone a process of critical revision. Methods In the framework of the BRENDA collective, we analyzed the benefits of CHT compared to HT in 4570 luminal A patients (pts) with primary diagnosis between 2001 and 2008. The results were adjusted by nodal status, age, tumor size and…

Oncologymedicine.medical_treatmentCancer Treatmentlcsh:MedicineBiochemistry0302 clinical medicineBreast TumorsMedicine and Health Sciences030212 general & internal medicinelcsh:ScienceAged 80 and overMultidisciplinaryPharmaceuticsHormonal TherapyEndocrine TherapyMiddle AgedSurvival RateOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleAnatomyResearch Articlemedicine.drugClinical OncologyAdultmedicine.medical_specialtyAnthracyclineBreast NeoplasmsDisease-Free SurvivalLymphatic System03 medical and health sciencesBreast cancerDrug TherapyDiagnostic MedicineInternal medicineBreast CancerCancer Detection and DiagnosismedicineChemotherapyHumansddc:610Survival rateGrading (tumors)AgedRetrospective StudiesChemotherapyTaxanebusiness.industrylcsh:RCancers and NeoplasmsBiology and Life SciencesRetrospective cohort studymedicine.diseaseHormonesSurgerylcsh:QLymph NodesClinical MedicinebusinessTamoxifenPLOS ONE
researchProduct

Mitotane Concentrations Influence Outcome in Patients With Advanced Adrenocortical Carcinoma

2020

Mitotane is the main option of treatment for advanced adrenocortical carcinoma (ACC). However, limited evidence is available regarding the impact of plasma mitotane levels on patient outcome. To address this question, we retrospectively analyzed patients with advanced ACC treated with mitotane for &ge

OncologymitotaneCancer Researchmedicine.medical_specialtyMultivariate analysisrecurrenceCombination therapyPrognosimedicine.medical_treatment030209 endocrinology & metabolismDiseaselcsh:RC254-282behavioral disciplines and activitiessurvivalArticle03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdrenocortical carcinomaMitotaneIn patientadrenal cancerObjective responseadrenal cancer; mitotane; prognosis; recurrence; survivalChemotherapybusiness.industrylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseOncology030220 oncology & carcinogenesisprognosisbusinessAdrenal cancer Mitotane Prognosis Recurrence Survivalmedicine.drug
researchProduct

Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study.

2006

Item does not contain fulltext BACKGROUND: Loss of TP53 function through gene mutation is a critical event in the development and progression of many tumour types including colorectal cancer (CRC). In vitro studies have found considerable heterogeneity amongst different TP53 mutants in terms of their transactivating abilities. The aim of this work was to evaluate whether TP53 mutations classified as functionally inactive (< or=20% of wildtype transactivation ability) had different prognostic and predictive values in CRC compared with mutations that retained significant activity. MATERIALS AND METHODS: TP53 mutations within a large, international database of CRC (n = 3583) were classified ac…

Oncologyp53MaleNutrition and Diseasebinding domainsLymphovascular invasionColorectal cancerDNA Mutational AnalysisAetiology screening and detection [ONCOL 5]Gene mutationmedicine.disease_causeTransactivationVoeding en ZiekteAntineoplastic Combined Chemotherapy ProtocolsDeterminants in Health and Disease [EBP 1]transcriptional activityMutationHematologyExonsMiddle AgedSurvival RateOncologyAdenocarcinomaFemaleColorectal Neoplasmsmedicine.medical_specialtyAdenocarcinomachemotherapy colorectal cancer mutation prognosis TP53 transactivational abilityMolecular epidemiology [NCEBP 1]Breast cancerTranslational research [ONCOL 3]Interventional oncology [UMCN 1.5]Internal medicinemedicineHumansNeoplasm InvasivenessSurvival rateneoplasmsbreast-cancerVLAGAgedNeoplasm StagingHereditary cancer and cancer-related syndromes [ONCOL 1]business.industryInternational Agenciesmedicine.diseaseImmunologyMutationTumor Suppressor Protein p53businessFollow-Up Studies
researchProduct

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK …

2013

Background: Combined inhibition of platelet-derived growth factor receptor beta signalling and vascular endothelial growth factor promotes vascular normalisation in preclinical models and may lead to increased delivery of chemotherapy to tumour tissue. This phase I/II trial assessed the safety and efficacy of capecitabine plus oxaliplatin (XELOX) plus bevacizumab and imatinib in the first-line treatment of patients with metastatic colorectal cancer. Methods: Two dose levels (I/II) were defined: capecitabine 850/1000 mg m−2 twice daily on days 1–14; oxaliplatin 100/130 mg m−2 on day 1; bevacizumab 7.5 mg kg−1 on day 1; imatinib 300 mg day−1 on days 1–21 every 21 days. The primary study endpo…

OncologysafetyAdultMaleCancer Researchmedicine.medical_specialtyBevacizumabOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentcolorectal cancerbevacizumabAntibodies Monoclonal HumanizedDeoxycytidineDisease-Free SurvivalDrug Administration SchedulePiperazinesCapecitabineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansProspective StudiesCapecitabineAgedAged 80 and overChemotherapybusiness.industrySunitiniboxaliplatinMiddle Agedmedicine.diseaseSurgeryOxaliplatinImatinib mesylatePyrimidinesTreatment OutcomeOncologyimatinibFluorouracilBenzamidesClinical StudyImatinib MesylateFemaleFluorouracilbusinessColorectal Neoplasmsmedicine.drugBritish Journal of Cancer
researchProduct

Clinical Presentation and Differential Diagnosis of Oral Cancer

2020

Over 90% of oral cancers are squamous cell carcinomas (OSCCs) which are of epithelial origin. Other types of malignancies account for the small remaining 10%. In this chapter, we describe the clinical characteristics of early- and advanced-stage OSCC and also consider the differential diagnosis of early-stage OSCC. The priority concern is to establish an early diagnosis, in order to secure the best possible prognosis and highest survival rate among oral cancer patients.

Oncologystomatognathic diseasesmedicine.medical_specialtybusiness.industryInternal medicinemedicineCancerOral CancersDifferential diagnosisPresentation (obstetrics)businessmedicine.diseaseSurvival rate
researchProduct

Galerkin Scheme-Based Determination of Survival Probability of Oscillators With Fractional Derivative Elements

2016

In this paper, an approximate semi-analytical approach is developed for determining the first-passage probability of randomly excited linear and lightly nonlinear oscillators endowed with fractional derivative elements. The amplitude of the system response is modeled as one-dimensional Markovian process by employing a combination of the stochastic averaging and the statistical linearization techniques. This leads to a backward Kolmogorov equation which governs the evolution of the survival probability of the oscillator. Next, an approximate solution of this equation is sought by resorting to a Galerkin scheme. Specifically, a convenient set of confluent hypergeometric functions, related to …

Operations researchMechanical EngineeringFractional derivative02 engineering and technologyCondensed Matter Physics01 natural sciencesFractional calculus020303 mechanical engineering & transportsSurvival Probability0203 mechanical engineeringSurvival probabilityMechanics of MaterialsScheme (mathematics)0103 physical sciencesNonlinear systemsApplied mathematicsFirst PassageSettore ICAR/08 - Scienza Delle CostruzioniGalerkin method010301 acousticsMathematicsJournal of Applied Mechanics
researchProduct

Membership duration in a Spanish union : a survival analysis

2013

Background of INCASI Project H2020-MSCA-RISE-2015 GA 691004. WP1: Compilation This article presents an analysis of the characteristics that are associated with union membership duration using data from the membership registers of the largest Spanish trade union: Comisiones Obreras (CCOO, Workers' Commissions). Making use of survival analysis techniques, the results indicate that the shortest membership durations and the highest risks of leaving are associated with workers with poor employment conditions, mainly youth and foreigners, as well as those in firms, economic sectors, and territories where the union has a rather weak presence. As workers in these situations represent the majority o…

Organizational Behavior and Human Resource ManagementLabour economicsTrade unionsStrategy and ManagementEconomic sectorUnion membershipGeneral Business Management and AccountingDual labor marketSociologiaManagement of Technology and InnovationTrade unionSindicatsEconomicsDuration (project management)Survival analysishealth care economics and organizations
researchProduct

Bcl-xL and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells

2008

AIM: To explore the role of Bcl-x(L) and Myeloid cell leukaemia (Mcl)-1 for the apoptosis resistance of colorectal carcinoma (CRC) cells towards current treatment modalities. METHODS: Bcl-x(L) and Mcl-1 mRNA and protein expression were analyzed in CRC cell lines as well as human CRC tissue by Western blot, quantitative PCR and immunohistochemistry. Bcl-x(L) and Mcl-1 protein expression was knocked down or increased in CRC cell lines by applying specific siRNAs or expression plasmids, respectively. After modulation of protein expression, CRC cells were treated with chemotherapeutic agents, an antagonistic epidermal growth factor receptor (EGFR1) antibody, an EGFR1 tyrosine kinase inhibitor, …

Organoplatinum CompoundsCell SurvivalCellbcl-X ProteinAntineoplastic AgentsApoptosisBcl-xLAdenocarcinomaBiologyIrinotecanTNF-Related Apoptosis-Inducing LigandDownregulation and upregulationhemic and lymphatic diseasesCell Line TumormedicineHumansRNA Messengerfas ReceptorViability assayneoplasmsColorectal CancerGastroenterologyGeneral MedicineTransfectionFas receptorMolecular biologydigestive system diseasesErbB ReceptorsOxaliplatinmedicine.anatomical_structureProto-Oncogene Proteins c-bcl-2ApoptosisCell cultureCancer researchbiology.proteinMyeloid Cell Leukemia Sequence 1 ProteinCamptothecinFluorouracilColorectal NeoplasmsWorld Journal of Gastroenterology
researchProduct

DNA Binding Studies and Cytotoxicity of a Dinuclear PtII Diazapyrenium- Based Metallo-supramolecular Rectangular Box

2012

The interaction with native DNA of a 2,7-diazapyrenium-based ligand 1 and its Pt II rectangular metal- lacycle 2 is explored through circular and linear dichroism and fluorescence spectroscopies. The metal-free ligand 1 binds through intercalation, with a binding constant of approximately 5 � 10 5 m � 1 , whereas the metallacycle 2 binds and bends the DNA with a bind- ing constant of 7 � 10 6 m � 1 . PCR assays show that metallo-supramolecular box 2 interferes with DNA transactions in vitro whereas the intercalator 1 does not. The metallacycle is active against four human cancer cell lines, with IC50 values ranging between 3.1 and 19.2 mm and shows similar levels of efficacy, but a differen…

Organoplatinum CompoundsCell SurvivalStereochemistryIntercalation (chemistry)Molecular ConformationSupramolecular chemistryAntineoplastic AgentsApoptosisLigandsNucleic Acid DenaturationLinear dichroismCatalysissupramolecular chemistryInhibitory Concentration 50chemistry.chemical_compoundCell Line TumorSettore BIO/10 - BiochimicaHumansmetallodrugPlatinumnoncovalent DNA bindingChemistryCircular DichroismOrganic ChemistryDNA NeoplasmGeneral ChemistrySettore CHIM/06 - Chimica OrganicaMetallacycleLigand (biochemistry)Binding constantFluorescenceSettore CHIM/08 - Chimica FarmaceuticaIntercalating AgentsKineticsSpectrometry FluorescenceSettore CHIM/03 - Chimica Generale E InorganicaThermodynamicscytotoxicityPtII rectangular boxCisplatinDNAPhenanthrolines
researchProduct

New heteronuclear gold(I)-platinum(II) complexes with cytotoxic properties: are two metals better than one?

2014

A series of mono- and heterodinuclear gold(I) and platinum(II) complexes with a new bipyridylamine-phosphine ligand have been synthesized and characterized. The X-ray structures of the ligand precursor 4-iodo-N,N-di(pyridin-2-yl)benzamide, and of one gold derivative are reported. All the complexes display antiproliferative properties in vitro in human cancer cells in the range of cisplatin or higher, which appear to correlate with compounds' uptake. Interestingly, studies of the interactions of the compounds with models of DNA indicate different mechanisms of actions with respect to cisplatin. The biological activity study of these complexes provides useful information about the interest of…

Organoplatinum CompoundsStereochemistryCell SurvivalPhosphinesPyridinesthioglucoseGOLD COMPOUNDSchemistry.chemical_elementAntineoplastic AgentsPLATINUM COMPLEXESBiochemistryRutheniumInorganic Chemistrychemistry.chemical_compoundStructure-Activity RelationshipGold CompoundsCoordination ComplexesCell Line TumormedicineHumansDNA bindingBenzamideBIOLOGICAL-PROPERTIESCell ProliferationCisplatinheteronuclear complexDERIVATIVESChemistryLigandCytotoxinsBiological activityBiological TransportDNAPYRIDINEanticancer agentRutheniumHeteronuclear moleculepolymerizationBenzamidesLIGANDSCisplatinGold complexesPlatinumOrganogold Compoundsmedicine.drugPlasmidsJournal of inorganic biochemistry
researchProduct